June 26th 2009
118
£595 / $1040 / €745
Targeted Delivery
By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.
Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.
The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.
Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products. There are significant opportunities for future commercial developments within the pharmaceutical industry. These include:
A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.
This report is part of a major new 4-volume strategic analysis
Drug Delivery Technologies:
Players, Products & Prospects to 2018
Focusing on the sectors that are driving growth
VOLUME I
CONTROLLED- RELEASE
VOLUME II
NANOTECHNOLOGY
VOLUME III
NUCLEIC ACID DELIVERY
VOLUME IV
TARGETED DELIVERY
Click here for details of the full report >>
Unique company & technology evaluation
It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.
In this report we present a précis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:
We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on their relative attributes.
Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:
Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:
About the Author
Dr Cheryl Barton is a highly regarded independent consultant with over 16 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer’s disease to schizophrenia. Dr Barton subsequently joined Dutch investment bank ABN Amro NV as a senior equity analyst where she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthélabo, and assessed the potential impact of new drug development on European Stocks.
In 2002, Dr Barton founded a consulting business (www.Pharmavision.co.uk) to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.